Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc oxide + propolis is a combination product typically formulated as a nanocomposite or nanoparticle system that merges the antimicrobial and antioxidant properties of zinc oxide (ZnO) with the bioactive compounds found in propolis. This combination has been developed to address challenges such as antibiotic resistance and oxidative stress. The mechanism involves both direct antibacterial action—where ZnO nanoparticles disrupt bacterial cell membranes—and synergistic effects from propolis, which contains flavonoids and phenolic acids that further enhance antimicrobial efficacy. Studies have shown this composite to be effective against Gram-positive and Gram-negative bacteria, including multidrug-resistant strains like Pseudomonas aeruginosa and Escherichia coli[1][5]. Additionally, the combination exhibits significant antioxidant activity and enzyme inhibition relevant for antidiabetic effects[5]. The formulation is often produced via green synthesis methods using plant-based extracts for safety and environmental compatibility[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc oxide + propolis.